Triamcinolone acetonide-assisted peeling of the internal limiting membrane

Kimura, Hideya; Kuroda, Shinichiro; Nagata, Makoto

doi:10.1016/s0002-9394(03)00782-7

Cited by 86 publications

(46 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, there were concerns regarding the safety of ICG use [21], and recent meta-analyses of ILM peeling in MH surgery showed that visual outcomes were significantly worse in the group with ICG application [22,23]. Trypan blue and triamcinolone acetonide have been used to replace ICG [24,25,26,27], but there are reports suggesting retinal toxic effects associated with these agents [28,29,30]. The recently introduced brilliant blue G (BBG) is thought to be a promising dye.…”

Section: Mh Surgerymentioning

confidence: 99%

Predicting Visual Outcome following Surgery for Idiopathic Macular Holes

Kusuhara

Negi

2013

Ophthalmologica

View full text Add to dashboard Cite

Since Kelly and Wendel [Arch Ophthalmol 1991;109:654-659] first reported successfully treating macular holes (MHs) using pars plana vitrectomy in 1991, MH surgery has been constantly improved. For example, introducing the removal of the internal limiting membrane considerably increased the closure rate of MHs, and the advent of microincision vitrectomy surgery reduced surgical trauma and decreased patient discomfort after surgery. As modern MH surgery can achieve a higher anatomical success rate and alleviate patients' postoperative distress, postoperative visual outcomes have lately become the primary concern. Informing patients of the expected visual acuity and visual improvement before surgery is ideal, but predicting postoperative visual outcomes is difficult because a large number of factors are associated with them. In this paper, we review previous studies and provide accumulating evidence for the relationship between individual prognostic factors and visual outcomes after MH surgery.

show abstract

Section: Mh Surgerymentioning

confidence: 99%

Predicting Visual Outcome following Surgery for Idiopathic Macular Holes

Kusuhara

Negi

2013

Ophthalmologica

View full text Add to dashboard Cite

show abstract

“…In several studies, intraocular TA was used intraoperatively during pars plana vitrectomy to visualize the inner limiting membrane, epiretinal membranes and remnants of the vitreous base [207,214,219,220,236]. Yamamoto et al [216] found that using TA during vitrectomy may facilitate both the removal of the epiretinal membrane around the macular hole and the separation of the residual vitreous cortex from the retina in highly myopic eyes with retinal detachment.…”

Section: Clinical Studies: Ta As Medical Device (Vitrectomy)mentioning

confidence: 99%

Intravitreal Triamcinolone

Tao

Jonas

2010

Ophthalmologica

View full text Add to dashboard Cite

Background: To provide an update on the intravitreal use of triamcinolone acetonide. Methods: Review of literature regarding triamcinolone-related research. Results: After the introduction of bevacizumab and ranibizumab into clinical practice, intravitreal triamcinolone has lost its leading position as the drug most often injected intravitreally. Due to its properties as a long-acting steroid, triamcinolone has still been used for various conditions such as diffuse diabetic macular edema, retinal vein occlusions, pseudophakic cystoid macular edema, chronic prephthisical ocular hypotony and uveitis, and in combination with bevacizumab or ranibizumab. The complications of intravitreal triamcinolone therapy include secondary ocular hypertension in about 40% of the eyes injected, cataract and postoperative infectious or noninfectious endophthalmitis. Conclusions: Due to its widespread biological effects as a steroid and due to a relatively large therapeutic window, intravitreal triamcinolone has remained in clinical use for a variety of intraocular disorders, and it may be a promising candidate for intravitreal medical combination therapies.

show abstract

“…Kimura et al [198] performed triamcinolone acetonide-assisted peeling of the internal limiting membrane [122,203,204] . Yamamoto et al [200] used intravitreal triamcinolone acetonide in 6 eyes during vitrectomy in highly myopic eyes with retinal detachment due to a macular hole.…”

Section: Pars Plana Vitrectomy Combined With Intravitreal Triamcinolomentioning

confidence: 99%

Intravitreal Triamcinolone Acetonide: A Change in a Paradigm

Jonas¹

2006

Ophthalmic Res

148

View full text Add to dashboard Cite

Background: Based on experimental studies and clinical observations by Robert Machemer, Gholam Peyman and others, the vitreous cavity has increasingly been used as a reservoir of drugs for the direct treatment of intraocular diseases. Methods and Results: The most widely injected drug so far has been triamcinolone acetonide for various intraocular neovascular and edematous diseases. Comparing the various diseases with respect to effect and side effects of the treatment, the best response in terms of gain in visual acuity has been achieved for intraretinal edematous diseases such as diffuse diabetic macular edema, branch retinal vein occlusion, central retinal vein occlusion, and pseudophakic cystoid macular edema. In eyes with various types of noninfectious uveitis including acute or chronic sympathetic ophthalmia and Adamantiadis-Behçet’s disease, visual acuity increased and the degree of intraocular inflammation decreased. Some studies have suggested that intra- vitreal triamcinolone may be useful as an angiostatic agent in eyes with iris neovascularization and proliferative ischemic retinopathies. Intravitreal triamcinolone may possibly be helpful as adjunct therapy for exudative age-related macular degeneration, particularly in combination with photodynamic therapy. In eyes with chronic, therapy-resistant ocular hypotony, intravitreal triamcinolone can induce an increase in intraocular pressure and may stabilize the eye. The complications of intravitreal triamcinolone therapy include secondary ocular hypertension in about 40% of the eyes injected; medically uncontrollable high intraocular pressure leading to antiglaucomatous surgery in about 1–2% of the eyes; posterior subcapsular cataract and nuclear cataract leading to cataract surgery in about 15–20% in elderly patients within 1 year after injection; postoperative infectious endophthalmitis with a rate of about 1:1,000; noninfectious endophthalmitis, perhaps due to a reaction to the solvent agent, and pseudoendophthalmitis with triamcinolone acetonide crystals appearing in the anterior chamber. Intravitreal triamcinolone injection can be combined with other types of intraocular surgery including cataract surgery, particularly in eyes with iris neovascularization. Cataract surgery performed some months after the injection does not show a markedly elevated complication rate. The injection may be repeated, if vision redecreases. In nonvitrectomized eyes, the duration of the effect and side effects of a single intravitreal injection of triamcinolone is about 6–9 months for a dosage of about 20 mg, and about 2–4 months for a dosage of 4 mg. It has remained unclear so far, whether and how to remove the solvent agent. In the future, intravitreal triamcinolone may be combined with other antiangiogenic drugs for the treatment of exudative age-related macular degeneration or with neuroprotective drugs for treatment of diabetic retinopathy. Conclusions: Despite an exponentially increasing number of mostly case-series studies, the intravitreal injection of triamcinolo...

show abstract

Triamcinolone acetonide-assisted peeling of the internal limiting membrane

Cited by 86 publications

References 5 publications

Predicting Visual Outcome following Surgery for Idiopathic Macular Holes

Predicting Visual Outcome following Surgery for Idiopathic Macular Holes

Intravitreal Triamcinolone

Intravitreal Triamcinolone Acetonide: A Change in a Paradigm

Contact Info

Product

Resources

About